Fri Sep 20 07:12:48 UTC 2024: ## Bank of New York Mellon Invests Heavily in Esperion Therapeutics

**New York, NY – September 20, 2024** – Bank of New York Mellon Corp (BNY Mellon) significantly increased its stake in Esperion Therapeutics, Inc. (NASDAQ: ESPR) during the second quarter, according to a recent SEC filing. The institutional investor now owns 572,323 shares of the biopharmaceutical company, after purchasing an additional 555,382 shares, representing a 3,278.3% increase. BNY Mellon’s holding in Esperion Therapeutics is currently valued at $1,271,000.

This move by BNY Mellon follows a trend of other institutional investors adjusting their holdings in Esperion Therapeutics. Bellevue Group AG increased its stake by 136.5% in the first quarter, while Vanguard Group Inc. boosted its holdings by 71.8% during the same period. New investors also entered the market, including Armistice Capital LLC and Susquehanna Fundamental Investments LLC. In total, institutional investors currently own 47.39% of Esperion Therapeutics’ stock.

Analysts are divided on the future prospects of ESPR. While StockNews.com upgraded the stock to a “buy” rating, Bank of America downgraded it to an “underperform” rating. Other analysts like HC Wainwright and Needham & Company LLC maintain a “buy” rating, although they have adjusted their target prices. Overall, the stock currently holds a “Hold” consensus rating with an average price target of $8.17.

Esperion Therapeutics is focused on developing and commercializing medications for patients with high LDL-C (low density lipoprotein cholesterol). Their key products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), oral medications used to lower LDL-C levels.

Esperion’s recent earnings report, released on August 12th, showed a net loss of $0.05 per share, exceeding analyst expectations of a $0.15 loss. The company reported revenue of $73.83 million, surpassing the estimated $51.90 million.

This significant investment by BNY Mellon and the overall positive sentiment from institutional investors suggest a potential for growth in Esperion Therapeutics. However, it’s important to consider the diverse opinions among analysts and the volatility of the biopharmaceutical sector before making any investment decisions.

Read More